GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Price-to-Owner-Earnings
中文

Surmodics (Surmodics) Price-to-Owner-Earnings

: 244.73 (As of Today)
View and export this data going back to 1998. Start your Free Trial

As of today (2024-04-23), Surmodics's share price is $26.92. Surmodics's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.11. It's Price-to-Owner-Earnings for today is 244.73.


The historical rank and industry rank for Surmodics's Price-to-Owner-Earnings or its related term are showing as below:

SRDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.76   Med: 43.96   Max: 1719.17
Current: 244.72

During the past 13 years, the highest Price-to-Owner-Earnings of Surmodics was 1719.17. The lowest was 17.76. And the median was 43.96.


SRDX's Price-to-Owner-Earnings is ranked worse than
93.57% of 280 companies
in the Medical Devices & Instruments industry
Industry Median: 31.17 vs SRDX: 244.72

As of today (2024-04-23), Surmodics's share price is $26.92. Surmodics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38. Therefore, Surmodics's PE Ratio for today is 70.84.

As of today (2024-04-23), Surmodics's share price is $26.92. Surmodics's EPS without NRI for the trailing twelve months (TTM) ended in was $0.47. Therefore, Surmodics's PE Ratio without NRI for today is 57.15.

During the past 13 years, Surmodics's highest PE Ratio without NRI was 816.10. The lowest was 15.06. And the median was 63.66.


Surmodics Price-to-Owner-Earnings Historical Data

The historical data trend for Surmodics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 297.02 286.60 - -

Surmodics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 330.45

Competitive Comparison

For the Medical Devices subindustry, Surmodics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics Price-to-Owner-Earnings Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Surmodics's Price-to-Owner-Earnings falls into.



Surmodics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Surmodics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=26.92/0.11
=244.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surmodics  (NAS:SRDX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Surmodics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Surmodics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines